Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder
Sponsor: Biohaven Pharmaceuticals, Inc.
This PHASE2/PHASE3 trial investigates Performance Anxiety and Social Anxiety Disorder and is currently completed. Biohaven Pharmaceuticals, Inc. leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jun 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 7 earlier versions
-
Mar 2021 — Jun 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Unknown Status → Active Not Recruiting
-
Nov 2019 — Feb 2020 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jul 2018 — Nov 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biohaven Pharmaceuticals, Inc.
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .